Literature DB >> 12476098

Office-based sutureless transconjunctival pars plana vitrectomy.

George F Hilton1, Robert G Josephberg, Lawrence S Halperin, Steven A Madreperla, Daniel A Brinton, Scott S Lee, Stephen F Gordon.   

Abstract

PURPOSE: This is a preliminary report to describe our technique of office-based vitrectomy (OVIT) and to report the incidence of complications over a 6-year period.
METHODS: In a retrospective, noncomparative case series, OVIT was performed on 225 patients in four participating offices. Each patient was operated on with a 23-gauge vitreous cutter that the authors have developed. They have also developed a 23-gauge transconjunctival infusion needle device. Diagnoses included endophthalmitis, uveitis, intravitreal lens fragments, ghost cell glaucoma, and rhegmatogenous retinal detachment.
RESULTS: The surgical goal was accomplished in all cases, but supplemental office procedures were required for two eyes, and a scleral buckle was necessary in one eye. There were 15 complications in 14 eyes: "fish-egg" gas bubbles (one eye), intraocular hemorrhage (nine eyes), choroidal detachment (two eyes), new retinal breaks (one eye), retinal detachment (one eye), and temporary elevation of intraocular pressure (one eye). The hemorrhages, choroidal detachments, and fish-egg bubbles all resolved spontaneously.
CONCLUSION: Office-based sutureless transconjunctival pars plana vitrectomy, with infusion when needed, is an effective operation for selected diseases of the posterior segment. In a multicenter series of 225 eyes, there were 15 complications in 14 (6%) eyes. Two of the complications were successfully managed with additional office procedures; one was managed in the operating room; and 12 resolved spontaneously.

Entities:  

Mesh:

Year:  2002        PMID: 12476098     DOI: 10.1097/00006982-200212000-00007

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  18 in total

1.  Expanded indications for 25-gauge transconjunctival vitrectomy.

Authors:  Hiroyuki Shimada; Hiroyuki Nakashizuka; Ryuzaburo Mori; Yoshihiro Mizutani
Journal:  Jpn J Ophthalmol       Date:  2005 Sep-Oct       Impact factor: 2.447

2.  [Pars-plana vitrectomy with anterior chamber infusion via a paracentesis in pseudophakic eyes].

Authors:  J C Schmidt; C H Meyer; S Mennel
Journal:  Ophthalmologe       Date:  2007-03       Impact factor: 1.059

3.  Comparative study of 23-gauge vitrectomy versus 20-gauge vitrectomy for the treatment of rhegmatogenous retinal detachment.

Authors:  Magali Albrieux; Frédéric Rouberol; Diane Bernheim; Jean-Paul Romanet; Christophe Chiquet
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-04-16       Impact factor: 3.117

4.  Office-based endoscopic revision using a microdebrider for failed endoscopic dacryocystorhinostomy.

Authors:  Jongyeop Park; Hochang Kim
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-06-24       Impact factor: 2.503

5.  One-port pars plana vitrectomy (by 25-G micro-incision).

Authors:  William Gualtieri
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-01-14       Impact factor: 3.117

6.  A phacovitrectomy with a clear corneal incision for a full-thickness macular hole.

Authors:  Nam Ju Kim; Hyeong Gon Yu
Journal:  Korean J Ophthalmol       Date:  2006-09

7.  Update on the prevention and treatment of endophthalmitis.

Authors:  Stephen G Schwartz; Harry W Flynn
Journal:  Expert Rev Ophthalmol       Date:  2014-08-23

8.  Trends in treatment strategies for suspected bacterial endophthalmitis.

Authors:  Greg D Fliney; Paula E Pecen; Jennifer N Cathcart; Alan G Palestine
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-02-07       Impact factor: 3.117

Review 9.  Ocular Infection: Endophthalmitis.

Authors:  Stephen G Schwartz; Harry W Flynn; Taraprasad Das; William F Mieler
Journal:  Dev Ophthalmol       Date:  2015-10-26

10.  Primary 23-gauge sutureless vitrectomy for rhegmatogenous retinal detachment.

Authors:  Mario R Romano; Ronald Das; Carl Groenwald; Theo Stappler; Joaquin Marticorena; Xavier Valldeperas; David Wong; Heinrich Heimann
Journal:  Indian J Ophthalmol       Date:  2012 Jan-Feb       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.